Skip to content
MARKETS / BALCAO / FOXO
BALCAO · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP

Foxo Technologies Inc. FOXO

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$16.4M
▲ 304.0% YoY
$-12.4M
$-3.9M
In brief

What this company does

FOXO Technologies Inc., is a healthcare services and technology company. We currently operate four synergistic divisions: (i) a rural hospital division; (ii) a mental and behavioral health division; (iii) an information, data and biospecimen sourcing division; and (iv) an epigenetics diagnostics and interpretation division. FOXO Technologies Inc., (“FOXO”) formerly known as Delwinds Insurance Acquisition Corp., a Delaware corporation, was originally formed in April 2020 as a publicly traded special purpose company for the purpose of effecting a merger, capital stock exchange, asset acquisition, reorganization, or similar business combination involving one or more businesses. The Company manages and classifies its business into three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs. Our Labs segment is commercializing proprietary epigenetic biomarker technology to be used for underwriting risk classification in the global life insurance industry. As of March 10, 2026 we had 192 employees, of which 117 were full-time.

Written from the business description in FOXO Technologies Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth
USD 16.4M
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 16.4 · Net income -12.4
8M16M-40M-80M20212022202320242025
Compound annual growth
+217.6%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−76 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -63.1% · Net -76.0%
1000%2000%3000%-5000%-10000%-15000%20212022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Each USD of equity lost 151 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -3.9
-8M-16M20212022202320242025

Total assetsUSD 44.6M
EquityUSD 11.1M
CashUSD 207,453.00
Current ratio0.11×

Equity funds 25% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0····
Net income $B−0.0−0.0−0.0−0.1−0.0
Free cash flow $B−0.0··−0.0−0.0
EPS, diluted $·−0.93−7.08−84.00−6.61
Dividend / sh $·····
Payout %·····
ROE %−151.0····
Shares out B·0.020.010.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 18 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 77 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityServices-Commercial Physical & Biological Research
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2021

Share this section

Download image